ENTX - Entera Bio Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.9300
+0.0200 (+1.05%)
At close: 3:56PM EDT

1.9100 -0.03 (-1.48%)
After hours: 7:09PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.9100
Open1.8900
Bid1.9000 x 1000
Ask1.9100 x 1200
Day's Range1.8800 - 2.0400
52 Week Range1.3500 - 4.1000
Volume241,602
Avg. Volume43,034
Market Cap35.192M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.8600
Earnings DateMay 21, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results

    Entera Bio Ltd. (ENTX), a leader in the development of orally delivered large molecule therapeutics, announced interim limited biomarker data from the ongoing Phase 2 clinical trial of EB613 in osteoporosis patients and results for the quarter ended March 31, 2020. The Company believes that the maximum efficacious dose has not yet been achieved and will continue the evaluation of the data from the existing patients including 6-month bone mineral density (BMD) results. Based on the favorable safety profile for patients on EB613 in the ongoing Phase 2 study, the Company intends to evaluate additional doses greater than 1.5mg to advance into a potential Phase 3 study, if appropriate.

  • The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows
    Benzinga

    The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows

    Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available online Thursday calling the shots. Earnings news flow continued to taper.Biopharma companies working on vaccines/therapies for COVID-19 continued to provide updates. Novavax, Inc. (NASDAQ: NVAX) shares more than doubled, thanks to an announcement concerning a $384 million grant from the Coalition for Epidemic Preparedness Innovations.Here are the key catalysts for the unfolding week.Conferences * UBS Virtual Global Healthcare Conference: May 18-20 * RBC Capital Markets 2020 Global Healthcare Virtual Conference: May 19-20 * European Society for Medical Oncology, or ESMO, Breast Cancer Virtual Meeting: May 23-24PDUFA Dates The FDA is due to rule on Aquestive Therapeutics Inc's (NASDAQ: AQST) NDA for apomorphine sublingual film (APL-130277), which is being evaluated for treating off episodes in Parkinson's disease patients. APL-130277 is being developed by Sunovion Pharmaceuticals, a subsidiary of Sumitomo Dainippon Pharma, in partnership with Aquestive.Clinical Readouts Entera Bio Ltd (NASDAQ: ENTX) is scheduled to report on Thursday interim three-month top-line biomarker data for the first 50% of the patients enrolled in the Phase 2 osteoporosis clinical trial of EB613.Oncolytics Biotech, Inc. (NASDAQ: ONCY) is due to present at the ESMO Breast Cancer Conference, interim biomarker data from the AWARE-1 early-stage breast cancer study that is evaluating its pelareorep along with Roche Holdings AG's (OTC: RHHBY) Tecentriq.See Also: Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna StandEarnings Monday Milestone Scientific Inc. (NYSE: MLSS) (before the market open) Adamis Pharmaceuticals Corp (NASDAQ: ADMP) (after the close)Tuesday Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (after the close) Ascendis Pharma A/S (NASDAQ: ASND) (after the close)Wednesday Mediwound Ltd (NASDAQ: MDWD) (before the market open) China Biologic Products Holdings Inc (NASDAQ: CBPO) (after the close)Thursday Entera Bio (before the market open) Medtronic PLC (NYSE: MDT) (before the market open) PAVmed Inc (NASDAQ: PAVM) (after the close) Xenon Pharmaceuticals Inc (NASDAQ: XENE) (after the close)IPO Quiet Period Expiry ORIC Pharmaceuticals Inc (NASDAQ: ORIC)See more from Benzinga * The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO * The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Entera Bio to Report Interim Data From EB613 Phase 2 Trial and First Quarter 2020 Business and Financial Results on May 21, 2020

    Entera Bio Ltd. (ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report interim three-month top-line biomarker data for the first 50% of the patients enrolled in the Phase 2 osteoporosis clinical trial of EB613 and financial and business results for the quarter ended March 31, 2020, on May 21, 2020, before the U.S. financial markets open. Entera’s management will host a conference call on Thursday, May 21, 2020 at 8:30 a.m. EDT to present the data and discuss the results for the quarter. A question-and-answer session will follow Entera’s remarks.

  • GlobeNewswire

    ENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019

    Entera Bio Ltd. (ENTX), a leader in the development of orally delivered large molecule therapeutics, announced its financial and operational results for the quarter and year ended December 31, 2019. Completed Phase 2 PK/PD trial of EB612 in hypoparathyroidism and presented the results at the 2019 Annual Meeting of the American Society for Bone and Mineral Research: The trial, which evaluated the Pharmacokinetic (PK) and Pharmacodynamic (PD) profile of EB612, was conducted in 16 patients and followed Entera’s prior clinical trials of oral human parathyroid hormone (PTH).

  • ACCESSWIRE

    Entera Bio Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Entera Bio Ltd. (NASDAQ:ENTX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 8:30 AM Eastern ...

  • GlobeNewswire

    ENTERA BIO TO REPORT 2019 BUSINESS AND FINANCIAL RESULTS ON MARCH 26, 2020

    Entera Bio Ltd. (ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report financial and business results for the quarter and year ended December 31, 2019, on March 26, 2020, before the U.S. financial markets open. To access a live audio webcast of the presentation on the “Investor Relations” page of the Entera’s website, please click here. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues.

  • Frost & Sullivan Releases Osteoporosis Drug Market Data
    PR Newswire

    Frost & Sullivan Releases Osteoporosis Drug Market Data

    Osteoporosis is defined as a systemic skeletal disorder characterized by low bone mass, deterioration of bone tissue leading to enhanced bone fragility, and a consequent increase in fracture risk. This asymptomatic condition often remains undiagnosed until it manifests as a low-trauma fracture which frequently leads to hospitalization.

  • GlobeNewswire

    Entera Bio Announces the Completion of $14.3 million Private Placement

    Entera Bio Ltd. (ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today that it increased the size of and completed its previously announced private placement offering (the “Offering”) with a select group of accredited investors (the “Purchasers”), bringing the anticipated aggregate gross proceeds to $14.3 million from the sale of an aggregate of 6,047,693 ordinary shares, par value NIS 0.0000769 per share (the “Shares”) at a price of $2.37 per share. In addition, as part of the offering, the Company has granted the Purchasers and certain finders an aggregate of 3,300,637 three-year warrants to purchase up to an additional 3,300,637 ordinary shares at an exercise price between $2.37 and $2.96 per share (the “Warrants” and together with the Shares, the “Securities”).

  • GlobeNewswire

    Entera Announces Closing of Private Placement

    Entera Bio Ltd. (ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has closed a private placement offering  (the “Offering”) with a select group of accredited investors, including certain board members or their affiliates (the “Purchasers”), under which it received gross proceeds of $11.8 million from the sale of 4,982,301 ordinary shares, par value NIS 0.0000769 per share at a price of $2.37 per share (the “Shares”). In addition, the Company has granted the Purchasers and certain finders an aggregate of 2,693,573 three-year warrants to purchase up to an additional 2,693,573 ordinary shares at an exercise price between $2.37 and $2.96 per share (the “Warrants” and together with the Shares, the “Securities”).

  • GlobeNewswire

    Entera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update

    Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020Presented Positive Results of a Phase 2 PK/PD study in.

  • GlobeNewswire

    Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

    Entera Bio Ltd. (ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, finance and administrative functions, and will lead the Company’s future financing efforts to support the company’s growth initiatives.

  • We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
    Simply Wall St.

    We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Entera Bio to Announce Third Quarter 2019 Financial Results on Thursday, November 21, 2019

    Entera Bio Ltd. (ENTX), announced today that it will report financial results for the third quarter and nine months ended September 30, 2019 before the U.S. financial markets open on Thursday, November 21, 2019. The Company will host a conference call at 8:30 am Eastern Time to discuss the results and provide a corporate update. A replay of the webcast will be archived on Entera website for approximately 45 days following the call.

  • PR Newswire

    Introducing Investors to Breakthrough Hi-tech and Bio-tech Companies: Frost & Sullivan Publishes Q2 Coverage for Investors to Make Informed Decisions

    NEW YORK , Oct. 7, 2019 /PRNewswire/ -- Equity research is published in the framework of Frost's Independent Equity Research Program. This type of equity research is trusted by investors as it is unbiased ...

  • GlobeNewswire

    Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism

    Entera Bio Ltd. (ENTX) today announced the presentation of positive results from its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug [Oral hPTH(1-34)].  The results were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Orlando, Florida on September 22, 2019. “Entera’s previous Phase 2 study in hypoparathyroid patients presented in 2016 showed that four times daily (QID) dosing of oral hPTH (1-34) had a positive effect on serum calcium, a reduction in serum phosphate and a reduction in urinary calcium.

  • Such Is Life: How Entera Bio (NASDAQ:ENTX) Shareholders Saw Their Shares Drop 51%
    Simply Wall St.

    Such Is Life: How Entera Bio (NASDAQ:ENTX) Shareholders Saw Their Shares Drop 51%

    Investing in stocks comes with the risk that the share price will fall. Unfortunately, shareholders of Entera Bio Ltd...

  • GlobeNewswire

    Entera Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    Entera Bio Ltd. (ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President of R&D, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 10:00 am Eastern Time. A live webcast of the presentation will be available via the “Investor Relations” page of the Entera Bio website, www.enterabio.com, or by clicking here.  A replay of the webcast will be archived on Entera website for approximately 45 days following the webcast. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs.

  • GlobeNewswire

    Entera Bio Reports Second Quarter 2019 Financial Results and Provides Operating Update

    Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results.

  • GlobeNewswire

    Entera Bio to Announce Second Quarter and Six Months ended June 30, 2019 Financial Results on Tuesday, August 20, 2019

    The Company will host a conference call at 8:30 am Eastern Time to discuss the results and provide a corporate update.  A live audio webcast of the presentation will be available via the “Investor Relations” page of the Entera Bio website, www.enterabio.com, or by clicking here.  A replay of the webcast will be archived on Entera website for approximately 45 days following the call. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The Company is initially applying its technology to develop an oral formulation of a human parathyroid hormone analog, Oral PTH (1-34), for treatment of hypoparathyroidism and osteoporosis.

  • GlobeNewswire

    Entera Bio Appoints Adam Gridley as Chief Executive Officer

    JERUSALEM, Israel, Aug. 05, 2019 -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip.

  • What Type Of Shareholder Owns Entera Bio Ltd.'s (NASDAQ:ENTX)?
    Simply Wall St.

    What Type Of Shareholder Owns Entera Bio Ltd.'s (NASDAQ:ENTX)?

    If you want to know who really controls Entera Bio Ltd. (NASDAQ:ENTX), then you'll have to look at the makeup of its...

  • GlobeNewswire

    Entera Announces Initiation of Phase 2 Dose Ranging Study for Oral PTH

    Entera Bio Ltd. (ENTX), announced today that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH (1-34) tablet. This double blinded, placebo controlled, dose-ranging study will evaluate three different doses in postmenopausal women with low bone mass. Human PTH (1-34) is a known anabolic treatment currently available as a daily subcutaneous injection, Forteo® (marketed by Eli Lilly®) with a known effect on bone formation biomarkers and bone mineral density (BMD).

  • PR Newswire

    From Injections to Pills - Entera Bio (ENTX): Initiation of Coverage by Frost & Sullivan

    Entera Bio recently entered into a $270 million license agreement with Amgen. Entera Bio's platform technology enables oral therapies based on molecules that would otherwise undergo gastric degradation and have limited or no bioavailability.

  • GlobeNewswire

    Entera Bio Reports First Quarter 2019 Financial Results and Operating Update

    Phase 2b Study for oral PTH in osteoporosis to begin by mid-year 2019Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Data processing and statistical.